Smad2 (Small Mothers Against Decapentaplegic Deleted in Pancreatic Carcinoma) (MaxLight 650)

Pab

MaxLight 650

4°C Do Not Freeze

Supplied as a liquid in PBS, pH 7.2. No preservatives added. Labeled with MaxLight™650.

A 27 amino acid synthetic peptide derived from the MH1 domain of human Smad2.

MaxLight™ 650 is a new Far-IR stable dye conjugate comparable to Alexa Fluor™647, DyLight™649, Cy5™ and offers better labeling efficiency, brighter imaging and increased immunodetection. Absorbance (655nm); Emission (676nm); Extinction Coefficient 250, 000.

Signaling events leading to transcriptional activation initiated by members of the TGF-beta superfamily are known to be mediated by SMAD proteins. Biological activities mediated by SMADs include cell growth and morphogenesis, development, and immune response. Activation by TGF-b is mediated by Smad2 and Smad3 while activation by bone morphogenetic protein (BMP) is mediated by Smad1 and Smad5. In contrast to the activating effects of these Smad proteins, Smad6 and Smad7, whose expression is also induced by ligand binding, appear to function as negative regulators of TGF-b superfamily signaling pathways.

Applications:
Suitable for use in FLISA and Western Blot. Other applications have not been tested.

Recommended Dilution:
FLISA: 0.1-1ug/ml
Western Blot: 1-3ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Store product at 4°C in the dark. DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight™650 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Note: Applications are based on unconjugated antibody.